Auranofin.

The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol (2008) 2.57

Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med (2007) 2.39

A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget (2013) 1.27

Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol (2002) 1.23

A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother (2013) 1.22

The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology (2012) 1.15

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci U S A (2015) 1.13

Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med (2011) 1.12

Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J Biol Inorg Chem (2009) 1.06

Auranofin: repurposing an old drug for a golden new age. Drugs R D (2015) 0.97

Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis. PLoS Negl Trop Dis (2015) 0.95

Metals and kidney autoimmunity. Environ Health Perspect (1999) 0.93

Bhasma : The ancient Indian nanomedicine. J Adv Pharm Technol Res (2014) 0.93

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget (2016) 0.90

A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis (2013) 0.86

Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J Biol Inorg Chem (2010) 0.86

Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents. PLoS One (2014) 0.83

Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway. Br J Pharmacol (2001) 0.82

Titanates deliver metal ions to human monocytes. J Mater Sci Mater Med (2009) 0.82

Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome. Antimicrob Agents Chemother (2010) 0.82

Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One (2013) 0.81

X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. J Struct Biol (2016) 0.80

Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. Future Med Chem (2016) 0.79

Gold(I)-triphenylphosphine complexes with hypoxanthine-derived ligands: in vitro evaluations of anticancer and anti-inflammatory activities. PLoS One (2014) 0.78

Allosteric cross-talk in chromatin can mediate drug-drug synergy. Nat Commun (2017) 0.78

Embryonic oxidative stress results in reproductive impairment for adult zebrafish. Redox Biol (2015) 0.76

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget (2016) 0.75

Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent. Antimicrob Agents Chemother (2016) 0.75

Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells. Biomol Ther (Seoul) (2016) 0.75

Cardiovascular and Hepatic Toxicity of Cocaine: Potential Beneficial Effects of Modulators of Oxidative Stress. Oxid Med Cell Longev (2015) 0.75

Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect Dis (2016) 0.75

Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs. Pharmacol Rev (2017) 0.75

Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol (1988) 35.68

Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med (1968) 27.34

Homoeopathic therapy in rheumatoid arthritis: evaluation by double-blind clinical therapeutic trial. Br J Clin Pharmacol (1980) 3.28

The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol (1987) 3.13

Occurrence of antibody to salivary duct epithelium in Sjogren's disease, rheumatoid arthritis, and other arthritides. A clinical and laboratory study. Ann Rheum Dis (1967) 2.43

Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. Q J Med (1967) 2.38

Measurement of joint inflammation. A radioisotopic method. Ann Rheum Dis (1970) 2.35

Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol (1983) 2.13

Defining morning stiffness in rheumatoid arthritis. J Rheumatol (1999) 2.12

Sjogren's syndrome. I. Sicca components. Q J Med (1973) 2.08

Sjögren's syndrome and autoimmunity in a geriatric population. Age Ageing (1972) 2.01

Hypothesis: that rheumatoid arthritis will disappear. J Rheumatol (1979) 2.01

Judging "current disease activity" in rheumatoid arthritis--an international comparison. J Rheumatol (1983) 2.01

Liver disease in Sjögren's syndrome and rheumatoid arthritis. Lancet (1970) 2.00

Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. Br Med J (1973) 1.97

A statistical aid to the diagnosis of keratoconjunctivitis sicca. Q J Med (1972) 1.81

Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis. Q J Med (1973) 1.80

Sjogren's syndrome. 2. Clinical associations and immunological phenomena. Q J Med (1973) 1.77

Gastric studies in sjögren's syndrome. Gut (1966) 1.73

A preliminary evaluation of the dimensionality and clinical importance of pain and disability in osteoarthritis of the hip and knee. Clin Rheumatol (1986) 1.70

Measurement of pain threshold in patients with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and healthy controls. Clin Rheumatol (1989) 1.69

Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol (1976) 1.69

Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications. Q J Med (1994) 1.67

Liver disease in rheumatoid arthritis and Sjøgren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction. Ann Rheum Dis (1975) 1.66

The articular scan in patients with rheumatoid arthritis: a possible method of quantitating joint inflammation using radio-technetium. Clin Sci (1968) 1.60

Salicylates and homoeopathy in rheumatoid arthritis: preliminary observations. Br J Clin Pharmacol (1978) 1.59

Derivation of knee joint synovial perfusion. Using the Xenon (133Xe) clearance technique. Ann Rheum Dis (1970) 1.59

Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. J Rheumatol (1992) 1.53

Depression in rheumatoid arthritis. J R Coll Gen Pract (1977) 1.52

HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA. Ann Rheum Dis (1992) 1.52

Radiological manifestations in 200 patients with ankylosing spondylitis: correlation with clinical features and HLA B27. J Rheumatol (1979) 1.52

Ibuprofen in rheumatoid arthritis. Clinical study of analgesic and anti-inflammatory activity. Ann Rheum Dis (1968) 1.47

Serum uric acid levels in normal pregnancy with observations on the renal excretion of urate in pregnancy. J Clin Pathol (1966) 1.43

Prior score availability: observations using the WOMAC osteoarthritis index. Br J Rheumatol (1991) 1.43

Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol (1973) 1.42

A short review of the relationship between intestinal permeability and inflammatory joint disease. Clin Exp Rheumatol (1990) 1.42

Immunological responses in Sjogren's syndrome and rheumatoid arthritis. Clin Exp Immunol (1971) 1.41

Serum sickness-like illness and leukocytoclastic vasculitis after intravenous streptokinase. J Am Acad Dermatol (1991) 1.40

Immunogenetics of polymyalgia rheumatica. Clin Exp Rheumatol (1994) 1.40

Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med (1990) 1.40

Are gallstones less prevalent in rheumatoid arthritis? Clin Rheumatol (1991) 1.39

Is diet important in rheumatoid arthritis? Br J Rheumatol (1991) 1.39

Evidence based medicine: the median is not the message. J Rheumatol (2001) 1.38

IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. J Biol Chem (1998) 1.37

Benefits of hospitalization in rheumatoid arthritis. Q J Med (1974) 1.37

Abnormalities in mineral metabolism suggestive of parathyroid over-activity in rheumatoid arthritis. Curr Med Res Opin (1975) 1.36

The McMaster Health Index Questionnaire as a measure of quality of life for patients with rheumatoid disease. J Rheumatol (1983) 1.35

Septic arthritis in patients with rheumatoid disease: a still underdiagnosed complication. J Rheumatol (1976) 1.31

Clinico-pharmacological studies and clinical evaluation of flurbiprofen. A new non-steroidal antirheumatic agent. Ann Rheum Dis (1972) 1.28

Rheumatoid arthritis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs--results of a consensus development (Delphi) exercise. J Rheumatol (1991) 1.28

Clinical studies on inflammation in human knee joints: xenon (133Xe) clearances correlated with clinical assessment in various arthritides and studies on the effect of intra-articularly administered hydrocortisone in rheumatoid arthritis. Clin Sci (1970) 1.27

Genetic and non-genetic factors in simple goitre formation: evidence from a twin study. Q J Med (1967) 1.25

Generalised and localised bone loss in patients with rheumatoid arthritis. Scand J Rheumatol (1975) 1.21

Association of Thyrotoxicosis and Auto-immune Thyroiditis. Br Med J (1961) 1.20

How safe are anti-rheumatic drugs? A study of possible iatrogenic deaths in patients with rheumatoid arthritis. Health Bull (Edinb) (1975) 1.19

Distribution of certain autoantibodies in monozygotic and dizygotic twins. Ann Rheum Dis (1966) 1.17

Outcome measurement in osteoarthritis clinical trials: the case for standardisation. Clin Rheumatol (1984) 1.17

Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol (1987) 1.16

Poor quality of posts in clinical rheumatology: a cause of failure to advance the specialty. Br Med J (1976) 1.15

Radioisotope study of small joint inflammation in rheumatoid arthritis. Ann Rheum Dis (1971) 1.15

Controlled trial of clinical utility of serum salicylate monitoring in rheumatoid arthritis. J Rheumatol (1984) 1.15

Continued use of non-steroidal anti-inflammatory drugs: an index of clinical efficacy. Br J Clin Pharmacol (1978) 1.14

Penetration of sodium fusidate (Fucidin) in the synovial cavity. Scand J Rheumatol (1972) 1.13

Antirheumatic drugs: clinical pharmacology and therapeutic use. Drugs (1980) 1.12

Pulmonary involvement in systemic lupus erythematosus. Ann Rheum Dis (1978) 1.11

Isotope studies in normal and diseased knee joints: 99mTc uptake related to clinical assessment and to synovial perfusion measured by the 133Xe clearance technique. Clin Sci (1971) 1.10

Serum uric acid in England and Scotland. Ann Rheum Dis (1977) 1.10

A comparative study of signal versus aggregate methods of outcome measurement based on the WOMAC Osteoarthritis Index. Western Ontario and McMaster Universities Osteoarthritis Index. J Rheumatol (1994) 1.10

Pulmonary infection and rheumatoid arthritis. Br J Dis Chest (1978) 1.10

Ankylosing spondylitis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs--results of a consensus development (Delphi) exercise. J Rheumatol (1991) 1.10

A comparative study of some commercially available tests for rheumatoid factor. J Clin Pathol (1974) 1.09

Relative roles of genetic and environmental factors in the control of serum uric acid levels in normouricaemic subjects. Ann Rheum Dis (1967) 1.08

NSAID and osteoarthritis--help or hindrance? J Rheumatol (1982) 1.07

Plasma immunoglobulin concentrations in twins. Clin Exp Immunol (1968) 1.07

Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. J Rheumatol (1976) 1.06

Osteoarthritis: symptoms, signs and source of pain. Inflammopharmacology (2004) 1.06

Precipitating antibodies to cellular antigens in Sjögren's syndrome, rheumatoid arthritis, and other organ and nonorgan-specific autoimmune diseases. Ann Rheum Dis (1978) 1.05

Individual differences in children's response to pain: role of temperament and parental characteristics. Pediatrics (1991) 1.05

Observations on drug prescribing in rheumatoid arthritis. Br Med J (1974) 1.05

Bone loss in patients with rheumatoid arthritis. Scand J Rheumatol (1975) 1.05

Ankylosing spondylitis antirheumatic drug trials. I. Effects of standardization procedures on observer dependent outcome measures. J Rheumatol (1991) 1.04

Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. Ann Rheum Dis (2002) 1.04

Indomethacin--aspirin interaction: a clinical appraisal. Br Med J (1975) 1.04

Corticosteroid-induced hypothalamo-pituitary-adrenal axis suppression. Prospective study using two regimens of corticosteroid therapy. Ann Rheum Dis (1968) 1.03

The detection of spinal pseudarthrosis in ankylosing spondylitis. Br J Radiol (1981) 1.01

Radiosensitivity of peripheral blood lymphocytes in autoimmune disease. Int J Radiat Biol Relat Stud Phys Chem Med (1985) 1.01

Bone-resorbing activity in the sera of patients with rheumatoid arthritis. Clin Sci Mol Med (1976) 1.00

Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. Ann Rheum Dis (1991) 1.00

Nursery outbreak of severe diarrhoea due to multiple strains of Pseudomonas aeruginosa. Lancet (1972) 1.00

Clinical evaluation of two strategies for improving patient recall of prior drug therapy. Br J Clin Pharmacol (1984) 1.00

Personal points of view--the need for expansion of medical social work facilities and personnel in rheumatology. Health Bull (Edinb) (1974) 1.00

Indices of inflammatory activity. Relationship between isotope studies and clinical methods. Ann Rheum Dis (1970) 0.99

Inheritance of ankylosing spondylitis and HL-A antigen W27. Lancet (1974) 0.98

Methods of assessment used in ankylosing spondylitis clinical trials: a review. Br J Rheumatol (1991) 0.98

The economics of arthritis. Bull Rheum Dis (1973) 0.98

Interactions of anti-rheumatic drugs. Agents Actions Suppl (1977) 0.97

Ankylosing spondylitis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials. J Rheumatol (1991) 0.97

Antinuclear factors in synovial fluids. Lancet (1967) 0.97

Some clinical observations on the diurnal rhythm of plasma cortisol (11-OHCS) in patients with rheumatoid arthritis treated with oral corticosteroid drugs. Curr Med Res Opin (1974) 0.97